Immucell price to free cash flow ICCC

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 22.1×
Peer median: 11.8×

Immucell's price to free cash flow is 22.1× as of Oct 23, 2026.

The median for 10 healthcare stocks of a similar size is 11.8×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.1×	21.0×	83.5×
2025	77.4×	30.4×	87.1×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	150×	150×	156×
2015	n/m a value too high to mean anything
2014	42.8×	12.0×	45.2×
2013	12.0×	11.9×	161×
2012	68.3×	66.9×	78.3×

Against its peers

Companies in Healthcare nearest Immucell's size, closest first, today.

Company	Price to free cash flow
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
LFVNLifevantage	11.0×
SPROSpero Therapeutics	n/m
APTAlpha Pro Tech	9.7×
ATNMActinium Pharmaceuticals	n/m
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
ELMDElectromed	26.2×
NEPHNephros	n/m
Peer median	11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Immucell

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.